Comparative Pharmacology
Head-to-head clinical analysis: KYLEENA versus SELFEMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYLEENA versus SELFEMRA.
KYLEENA vs SELFEMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses endometrial proliferation, thickens cervical mucus, and induces endometrial atrophy. It also partially inhibits ovulation.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptor alpha (ERα), inducing its degradation and inhibiting estrogen-dependent cell proliferation.
KYLEENA (levonorgestrel-releasing intrauterine system 19.5 mg) is inserted into the uterine cavity by a healthcare professional. One system releases levonorgestrel at approximately 17.5 mcg/day initially, decreasing to 7.4 mcg/day after 1 year and 5.1 mcg/day after 3 years, and is effective for up to 5 years.
1 tablet (50 mg) orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 25 hours (range 18–30 hours) after repeated dosing; supports once-daily dosing but not applicable for IUD as systemic absorption is minimal.
Terminal elimination half-life of 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min).
Renal (fecal negligible). Levonorgestrel is extensively metabolized; metabolites are excreted primarily in urine (40–68%) and to a lesser extent in feces (16–48%).
Primarily renal excretion as unchanged drug (50-60%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal